Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

94.74USD
16 Aug 2019
Change (% chg)

$1.43 (+1.53%)
Prev Close
$93.31
Open
$93.92
Day's High
$94.84
Day's Low
$93.27
Volume
965,644
Avg. Vol
1,484,670
52-wk High
$98.97
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

U.S. FDA Approves Inrebic As First New Treatment In Nearly A Decade For Patients With Myelofibrosis
Friday, 16 Aug 2019 10:30am EDT 

Aug 16 (Reuters) - Celgene Corp ::U.S. FDA APPROVES INREBIC® (FEDRATINIB) AS FIRST NEW TREATMENT IN NEARLY A DECADE FOR PATIENTS WITH MYELOFIBROSIS.CELGENE CORP - INREBIC PROVIDES NEW, ONCE-DAILY ORAL OPTION FOR PATIENTS AFFECTED BY RARE BONE MARROW CANCER.  Full Article

FDA Says Granted Approval Of Inrebic To Impact Biomedicines, A Unit Of Celgene Corporation
Friday, 16 Aug 2019 09:46am EDT 

Aug 16 (Reuters) - FDA: :FDA SAYS GRANTED APPROVAL OF INREBIC TO IMPACT BIOMEDICINES, INC., A UNIT OF CELGENE CORPORATION .FDA APPROVES TREATMENT FOR PATIENTS WITH RARE BONE MARROW DISORDER.  Full Article

Soros Fund Management LLC Ups Share Stake In Celgene
Wednesday, 14 Aug 2019 04:05pm EDT 

Aug 14 (Reuters) - Soros Fund Management LLC::Soros Fund Management LLC UPS SHARE STAKE IN CELGENE CORP TO 817,385 SHARES FROM 407,140 SHARES - SEC FILING.SOROS FUND MANAGEMENT LLC - CHANGE IN HOLDINGS ARE AS OF JUNE 30, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF MARCH 31, 2019.  Full Article

Bristol-Myers Announces European Commission Approval Of Pending Celgene Deal
Monday, 29 Jul 2019 10:10am EDT 

July 29 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES EUROPEAN COMMISSION APPROVAL OF PENDING ACQUISITION OF CELGENE.INTENDS TO CLOSE CELGENE TRANSACTION AT EARLIEST POSSIBLE DATE, WHICH IT EXPECTS TO BE BY END OF 2019 OR BEGINNING OF 2020..  Full Article

Bristol-Myers Qtrly Non-GAAP EPS $1.18
Thursday, 25 Jul 2019 06:59am EDT 

July 25 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB - QTRLY GAAP EPS $0.87, QTRLY NON-GAAP EPS $1.18; QTRLY REVENUE $6.27 BILLION, UP 10%.Q2 EARNINGS PER SHARE VIEW $1.07, REVENUE VIEW $6.11 BILLION -- REFINITIV IBES DATA.BRISTOL-MYERS SQUIBB - DECREASING 2019 GAAP EPS GUIDANCE FROM $3.84 - $3.94 TO $3.73 - $3.83.FY2019 EARNINGS PER SHARE VIEW $4.16 -- REFINITIV IBES DATA.BRISTOL-MYERS SQUIBB - EXPECTS TO CLOSE CELGENE TRANSACTION BY END OF 2019 OR BEGINNING OF 2020.BRISTOL-MYERS SQUIBB - GUIDANCE INCLUSIVE OF CELGENE ACQUISITION WILL BE PROVIDED AFTER CLOSE OF TRANSACTION.BRISTOL-MYERS SQUIBB - INCREASING 2019 NON-GAAP EPS GUIDANCE FROM $4.10 - $4.20 TO $4.20 - $4.30.BRISTOL-MYERS SQUIBB - U.S. REVENUES ROSE 14% TO $3.7 BILLION IN QUARTER.BRISTOL-MYERS SQUIBB - RESEARCH AND DEVELOPMENT EXPENSES FELL 45% TO $1.3 BILLION IN QUARTER MAINLY DUE TO $1.1 BILLION CHARGE FROM NEKTAR COLLABORATION IN Q2 LAST YEAR.BRISTOL-MYERS SQUIBB - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $30.4 BILLION AS OF JUNE 30.BRISTOL-MYERS SQUIBB - QTRLY OPDIVO WORLDWIDE REVENUE $1.82 BILLION, UP 12%; QTRLY ELIQUIS WORLDWIDE REVENUE $2.04 BILLION, UP 24%.  Full Article

Jounce Therapeutics Announces Update On Strategic Collaboration With Celgene Corp
Tuesday, 23 Jul 2019 04:00pm EDT 

July 23 (Reuters) - Jounce Therapeutics Inc ::JOUNCE THERAPEUTICS ANNOUNCES UPDATE ON STRATEGIC COLLABORATION WITH CELGENE CORPORATION.JOUNCE THERAPEUTICS INC - CELGENE LICENSES JTX-8064, RESULTING IN $50.0 MILLION UPFRONT PAYMENT TO JOUNCE.JOUNCE THERAPEUTICS INC - JOUNCE RETAINS FULL WORLDWIDE RIGHTS TO VOPRATELIMAB, JTX‑4014 AND ALL DISCOVERY PROGRAMS.JOUNCE THERAPEUTICS INC - JOUNCE RETAINS FULL WORLDWIDE RIGHTS TO VOPRATELIMAB, JTX‑4014 AND ALL DISCOVERY PROGRAMS.JOUNCE THERAPEUTICS INC - UNDER TERMS OF NEW LICENSE AGREEMENT FOR JTX-8064, JOUNCE RECEIVES A $50.0 MILLION NON-REFUNDABLE LICENSE FEE.JOUNCE THERAPEUTICS INC - CELGENE WILL BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION OF JTX-8064..JOUNCE THERAPEUTICS INC - REMAINS ON TRACK TO IDENTIFY RECOMMENDED PHASE 2 DOSE OF JTX-4014 IN 2019..JOUNCE THERAPEUTICS INC - ELIGIBLE TO GET FROM CELGENE UP TO $480 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS.JOUNCE THERAPEUTICS INC - JOUNCE EXPECTS TO REPORT PRELIMINARY EFFICACY DATA AND BIOMARKER RELATIONSHIPS TO CLINICAL OUTCOMES FROM EMERGE IN 2020.JOUNCE THERAPEUTICS INC - JOUNCE NOW EXPECTS TO RECORD APPROXIMATELY $50.0 MILLION IN CASH REVENUE IN 2019 RELATED TO LICENSE OF JTX-8064.JOUNCE - CONTINUES TO EXPECT GROSS CASH BURN ON OPERATING EXPENSES, CAPITAL EXPENDITURES FOR FY TO BE ABOUT $80.0 MILLION TO $95.0 MILLION.  Full Article

Bristol-Myers Squibb Announces Extension Of The Expiration Date For Exchange Offers For Celgene Notes
Friday, 28 Jun 2019 06:59am EDT 

June 28 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES EXTENSION OF THE EXPIRATION DATE FOR EXCHANGE OFFERS FOR CELGENE CORPORATION NOTES.BRISTOL-MYERS SQUIBB - SETTLEMENT DATE FOR EXCHANGE OFFERS IS EXPECTED TO OCCUR PROMPTLY AFTER EXPIRATION DATE AND ON OR ABOUT CLOSING DATE OF MERGER.BRISTOL-MYERS SQUIBB - EXTENDS SUCH EXPIRATION DATE TO 5:00 P.M., NEW YORK CITY TIME, ON SEPTEMBER 30.  Full Article

Celgene Corp Says U.S. FDA And EMA Accept Applications For Ozanimod For Treatment Of Relapsing Forms Of Multiple Sclerosis
Thursday, 6 Jun 2019 07:43am EDT 

June 6 (Reuters) - Celgene Corp ::CELGENE CORP - U.S. FDA AND EMA ACCEPT APPLICATIONS FOR OZANIMOD FOR TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS.CELGENE - UNDER PRESCRIPTION DRUG USER FEE ACT, FDA HAS SET ACTION DATE AS MARCH 25, 2020.CELGENE CORP - REGULATORY DECISION FROM EUROPEAN MEDICINES AGENCY IS EXPECTED IN FIRST HALF OF 2020.  Full Article

Bristol-Myers Says David Elkins Will Be Appointed Co's Executive Vice President & CFO
Wednesday, 5 Jun 2019 06:59am EDT 

June 5 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES POST-CLOSING LEADERSHIP TEAM.BRISTOL-MYERS SQUIBB CO - SAMIT HIRAWAT WILL JOIN BRISTOL-MYERS SQUIBB AS CHIEF MEDICAL OFFICER, GLOBAL DRUG DEVELOPMENT.BRISTOL-MYERS SQUIBB CO - DAVID ELKINS WILL BE APPOINTED COMPANY'S EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.BRISTOL-MYERS SQUIBB CO - RUPERT VESSEY , WILL SERVE AS PRESIDENT, RESEARCH & EARLY DEVELOPMENT.BRISTOL-MYERS SQUIBB CO - CAFORIO WILL CONTINUE TO SERVE AS CHAIRMAN OF BOARD AND CHIEF EXECUTIVE OFFICER OF COMPANY.BRISTOL-MYERS SQUIBB CO - DAVID ELKINS IS CURRENTLY CHIEF FINANCIAL OFFICER OF CELGENE.BRISTOL-MYERS - FOLLOWING DEAL CLOSE, CHARLES BANCROFT TO WORK WITH ELKINS TO ENSURE AN EFFECTIVE TRANSITION OF ALL FINANCIAL AND OPERATIONAL MATTERS.BRISTOL-MYERS SQUIBB CO - CHRIS BOERNER WILL CONTINUE IN HIS ROLE AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIALIZATION OFFICER.  Full Article

FDA Approves Revlimid In Combination With Rituximab For Treatment Of Follicular Lymphoma Or Marginal Zone Lymphoma
Tuesday, 28 May 2019 12:30pm EDT 

May 28 (Reuters) - Celgene Corp ::FDA APPROVES REVLIMID (LENALIDOMIDE) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA OR MARGINAL ZONE LYMPHOMA.CELGENE CORP - MAA FOR REVLIMID IN COMBINATION WITH RITUXIMAB IS UNDER REVIEW BY EMA FOR TREATMENT OF RELAPSED/REFRACTORY FL AND MZL.  Full Article

FDA approves Celgene's bone marrow cancer treatment

The U.S. Food and Drug Administration on Friday approved Celgene Corp's Inrebic to treat certain rare forms of bone marrow cancer called myelofibrosis, making it the second approved drug to treat the disease.